Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Mar 29, 2014 5:28pm

134 Views

Post# 22386278

Linda strikes back!

In her reply to Feurstein she does not pull any punches. I know some people would say to ignore the analyst but I like her hitting back! Maybe we will fail but AF will still be an ass, his anlaysis is shallow and thin. We are not a sure thing and we will not come close to our phase one that's just the way it is. I'm hoping for a third of phase one which is still very approvable. Direct would be frosting on the cake and we will know a lot more when we present at ASCO.

Bullboard Posts

Gold vs. bitcoin, where should you invest?